Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
66
-
Total 13F shares, excl. options
-
51.3M
-
Shares change
-
+476K
-
Total reported value, excl. options
-
$342M
-
Value change
-
+$1.99M
-
Put/Call ratio
-
0.68
-
Number of buys
-
33
-
Number of sells
-
-26
-
Price
-
$6.68
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q4 2017
78 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q4 2017.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.3M shares
of 1.57B outstanding shares and own 3.26% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (12.2M shares), NEA Management Company, LLC (12M shares), Capital World Investors (6.79M shares), FMR LLC (4.63M shares), BAILLIE GIFFORD & CO (1.92M shares), ORBIMED ADVISORS LLC (1.91M shares), ORACLE INVESTMENT MANAGEMENT INC (1.03M shares), RENAISSANCE TECHNOLOGIES LLC (994K shares), Tekla Capital Management LLC (935K shares), and Rock Springs Capital Management LP (875K shares).
This table shows the top 66 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.